Quick Answer
FATE THERAPEUTICS INC reported Cash and Equivalents of $46.63 million for fiscal year 2025.
FATE THERAPEUTICS INC Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $46.63M | +29.3% |
| 2024 | $36.06M | -13.9% |
| 2023 | $41.87M | -31.7% |
| 2022 | $61.33M | -54.1% |
| 2021 | $133.58M | -20.2% |
| 2020 | $167.35M | +67.7% |
| 2019 | $99.81M | -47.6% |
| 2018 | $190.51M | +114.2% |
| 2017 | $88.95M | +0.4% |
| 2016 | $88.61M | +36.7% |
| 2015 | $64.81M | +32.0% |
| 2014 | $49.10M | -9.1% |
| 2013 | $54.04M | +494.7% |
| 2012 | $9.09M | +42.3% |
| 2011 | $6.39M | -43.1% |
| 2010 | $11.22M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $40.62M | +7.2% | -1.5% |
| June 30, 2025 | $41.25M | +11.7% | -8.2% |
| March 31, 2025 | $44.92M | -63.0% | +24.6% |
| December 31, 2024 | $36.06M | -13.9% | -4.9% |
| September 30, 2024 | $37.91M | +13.7% | +2.7% |
| June 30, 2024 | $36.92M | -21.1% | -69.6% |
| March 31, 2024 | $121.32M | +188.7% | +189.8% |
| December 31, 2023 | $41.87M | -31.7% | +25.6% |
- FATE THERAPEUTICS INC showed an increase of +29.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2010–2025 period, FATE THERAPEUTICS INC’s cash and equivalents has grown by 315.4% (from $11.22 million to $46.63 million).
- The most recent figure is from FATE THERAPEUTICS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: